Macro Strategy - The LPR remained unchanged in November, with the 1-year and 5-year rates at 3.00% and 3.50% respectively, indicating stable monetary policy despite weak macro data in October [2][3] - A-share indices experienced significant declines from November 17 to 21, with the Shanghai Composite Index down 3.90% and the ChiNext Index down 6.15%, primarily due to reduced expectations for a December rate cut by the Federal Reserve [3][4] - All primary industries in the A-share market declined, with energy metals and communication equipment showing the highest cumulative gains for 2025 at 83.18% and 78.97% respectively [5][6] Investment Recommendations - For the long term, 2026 is expected to be a year of growth driven by the "14th Five-Year Plan," with a stable A-share market anticipated [7] - Short-term strategies should focus on sectors benefiting from long-term capital inflows, traditional sectors related to "anti-involution," and consumer areas such as motorcycles and medical services [7] North Exchange Overview - As of November 21, 2025, the North Exchange had 284 listed stocks, with an average total market value of 864.16 billion yuan, a decrease of 4.16% from the previous week [10][11] - Notable new listings included Dapeng Industrial, which saw a 1211.11% increase in its stock price during its first week [10][12] Medical Services Industry - The pharmaceutical and biological sector fell by 6.88%, underperforming the Shanghai Composite Index by 3.11 percentage points [16][17] - The medical services sector's PE ratio is currently at 31.22, with a recent decline of 2.25 [18] - High-growth areas such as ADC and TIDES CDMO are recommended for investment, with companies like WuXi AppTec and WuXi Biologics highlighted [19][20][21] Automotive Industry - Yuanrong Qixing showcased 200,000 mass-produced vehicles at the Guangzhou Auto Show, aiming for a cumulative delivery of 1 million vehicles by 2026 [23][24] - The automotive sector is expected to benefit from the acceleration of intelligent technology adoption and supportive policies for vehicle consumption [25][26] - Investment opportunities are significant in the automotive and parts sectors, particularly for companies involved in smart components and electric vehicles [26][27]

Investment Rating - The industry maintains an "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [5]. Core Insights - The demand for respiratory medications is expected to rise due to the increase in flu cases, with a reported 955 flu-like illness outbreaks, marking a 53.8% increase from the previous week [4]. - The market performance of the Traditional Chinese Medicine (TCM) sector showed a decline of 6.46% last week, ranking second among secondary pharmaceutical sectors [1]. - The TCM sector's Price-to-Earnings (PE) ratio (ttm) is 27.36X, down by 1.89X week-on-week, while the Price-to-Book (PB) ratio (lf) is 2.31X, down by 0.16X [2]. Market Performance - The TCM sector reported a closing index of 6419.16 points, down 6.46% for the week, while the overall pharmaceutical sector index fell by 6.88% [1][16]. - Among companies, *ST Changyao, Weikang Pharmaceutical, Jiangzhong Pharmaceutical, Yunnan Baiyao, and Dong'e Ejiao showed better performance, while Te Yi Pharmaceutical, Panlong Pharmaceutical, Zhendong Pharmaceutical, Yiling Pharmaceutical, and Enwei Pharmaceutical lagged [1]. Valuation Metrics - The TCM sector's PE ratio is at the 28.94% percentile since 2013, while the PB ratio is at the 5.93% percentile, indicating relatively low valuation compared to historical data [2]. Supply Chain Insights - The market for TCM raw materials is currently weak, with a price index of 224.73 points, reflecting a 0.3% decrease due to oversupply and inventory buildup [3]. Investment Recommendations - Three main investment themes are highlighted: 1. Price governance focusing on competitive advantages and innovation capabilities [5]. 2. Consumption recovery driven by macroeconomic improvement and aging population [5]. 3. State-owned enterprise reform, which is expected to enhance efficiency and performance [5]. Target Companies - Recommended companies include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on those with strong R&D capabilities and unique products [9].

Investment Rating - Industry rating: Maintain "Overweight" [4] Core Views - The rare earth magnetic materials industry has continued its downward trend, with a 5.29% decline this week, underperforming the benchmark (CSI 300) by 1.52 percentage points [6][13] - The current industry valuation (TTM P/E) has decreased by 3.97x to 69.94x, which is at 84.1% of the historical percentile [6][13] - Light rare earth concentrate prices have rebounded, while medium and heavy rare earth prices have slightly declined [7][10] - The market sentiment remains cautious, with expectations of price stabilization and potential upward trends in the future due to tightening supply and improving demand [10][44] Summary by Sections Market Performance - The rare earth magnetic materials sector has seen a relative return of -12% over the past month, -9% over three months, and a positive 46% over the past year [5] - Absolute returns are -15% for one month, -5% for three months, and 57% for twelve months [5] Price Movements - Light rare earth concentrate prices have increased by 2.86% to 3.6 million CNY/ton, 3.23% to 3.2 million CNY/ton, and 3.85% to 2.7 million CNY/ton for different mines [10] - The average price of praseodymium-neodymium oxide has risen by 0.73% to 549,000 CNY/ton, while praseodymium-neodymium metal has slightly decreased by 0.15% [15][17] - Dysprosium prices have continued to decline by 1.66% to 1,485 CNY/kg, and terbium prices have also decreased [22] Investment Recommendations - The report maintains an "Overweight" rating, suggesting that despite high valuation pressures, the expected recovery in rare earth prices and demand could lead to improved profitability for downstream magnetic material companies [44][45] - It is recommended to focus on upstream rare earth resource companies and downstream magnetic material companies with strong customer structures and growth potential [11][45]

Core Insights - The report indicates that the market has experienced significant fluctuations, with the Shanghai Composite Index and the CSI 1000 Index showing contrasting performances in the recent week and year-to-date [3][5][20] - The CSI 1000 Index enhancement strategy has shown a year-to-date return of 21.60%, outperforming the benchmark index by 2.97% [4][18] Market Performance - In the week of November 17-21, 2025, the Shanghai 50 and CSI Dividend Index had the best performances with returns of -2.72% and -3.69%, while the Micro-cap Index and ChiNext Index had the worst returns at -7.80% and -6.15% respectively [3][7] - Year-to-date, the Micro-cap Index and ChiNext Index led with returns of 66.12% and 36.35%, while the CSI Dividend and Shanghai 50 Index lagged with returns of -0.48% and 10.10% [8][20] Strategy Performance - For the week, the CSI 1000 Index enhancement strategy yielded a return of -5.89%, slightly underperforming the index return of -5.80, resulting in an excess return of -0.09% [4][12] - For the month, the strategy's return was -6.45%, compared to the index's -5.85%, leading to an excess return of -0.60% [16] - Year-to-date, the strategy has achieved a return of 21.60%, outperforming the index return of 18.63% by 2.97% [18] Investment Recommendations - The report suggests that the CSI 1000 Index has shown weak performance recently, attributed to external uncertainties and internal market pressures, indicating a potential for continued volatility [5][20] - The report emphasizes the need for investors to be cautious of the high volatility associated with the CSI 1000 Index, as it may face significant downward pressure in the near term [5][20]

证券研究报告 2025 年 11 月 23 日 湘财证券研究所 行业研究 银行业周报 净息差边际趋稳，巩固核心盈利能力 | 1. | 《2025年中期策略-价值重估仍 | | --- | --- | | 在进行时》 | 2025.07.02 | | 2. | 《业绩底部修复，配置价值提 | | 升》 | 2025.09.05 | | % | 1 个月 | 3 | 个月 | 12 | 个月 | | --- | --- | --- | --- | --- | --- | | 相对收益 | 5.9 | | -5.6 | | 5.0 | | 绝对收益 | 2.6 | | -1.8 | | 16.7 | 分析师：郭怡萍 证书编号：S0500523080002 Tel：(8621) 50295327 Email：guoyp@xcsc.com 地址：上海市浦东新区银城路88号中 国人寿金融中心10楼 相关研究： 核心要点： 三季度监管指标：净息差边际趋稳，巩固核心盈利能力 2. 《业绩底部修复，配置价值提 国家金融监管总局发布 2025 年三季度商业银行主要监管指标。三季度商业 银行监管数据呈现核心盈利能力改善态势，部分银 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Viewpoints - The flu activity has risen to near three-year highs, highlighting the urgent demand for flu and related vaccines, and structural opportunities in the flu vaccine market should be closely monitored [5][9] - Recent developments in vaccine companies include clinical trial applications for new vaccines, indicating ongoing innovation and regulatory support for the industry [4][5] - The industry is experiencing a transition from scale expansion to innovation-driven growth, with a focus on high-tech barriers and differentiated pipeline layouts [9][10] Summary by Relevant Sections Recent Industry Performance - The vaccine sector has seen a relative decline of 28% over the past 12 months compared to the CSI 300 index, with a recent absolute decline of 14% [4][6] - The vaccine sector's PE (ttm) is 94.34X, down 7.53X from the previous period, while the PB (lf) is 1.85X, reflecting a decrease of 0.14X [8] Market Dynamics - The National Influenza Center reported a 53.8% increase in flu-like illness cases, with significant activity in both northern and southern provinces [4][5] - The China Vaccine Industry Association has advocated against "involutionary" competition to promote high-quality development in the vaccine sector [4] Investment Recommendations - The vaccine industry is under pressure, with a focus on finding alpha opportunities amid differentiation. Long-term attention should be given to innovation and international expansion [9][10] - Companies with strong R&D capabilities and differentiated products, such as CanSino and Kanghua Biotech, are recommended for investment [10][27]

Group 1: New Materials Industry - The rare earth magnetic materials industry experienced a decline of 4.08% this week, underperforming the benchmark by 3 percentage points [2] - The industry valuation (TTM P/E) fell by 3.32 times to 73.9 times, currently at 87.2% of its historical percentile [2] - Prices of rare earth concentrates showed a slight decline, with mixed carbonate rare earth ore prices dropping by 2.78% [3] - Praseodymium and neodymium prices peaked and then fell, with praseodymium oxide average price decreasing by 1.8% [3] - Dysprosium prices continued to decline, with an average decrease of 2.58% for dysprosium oxide [4] - The price of sintered neodymium-iron-boron N35 decreased by 1.45%, indicating weak demand and limited order releases [4] Group 2: Investment Recommendations - The short-term prices in the rare earth sector are driven by market sentiment, with supply expected to decrease before the end of the year, while demand remains positive [5] - The overall valuation and performance levels are supported by loose liquidity and industrial policies, but high valuations may face pressure due to declining market risk appetite [5] - The industry maintains an "overweight" rating, with expectations for price recovery and improved market conditions following the easing of export controls [6] - Focus on upstream rare earth resource companies is recommended due to expected supply contraction and strategic value positioning [6] - Downstream magnetic material companies are also expected to benefit from price recovery, particularly those with strong customer structures and new growth opportunities [6] Group 3: Food and Beverage Industry - The food and beverage industry saw a decline of 0.56% from November 3 to November 7, while outperforming the broader market indices [8] - The industry valuation is currently at a low level, with a PE ratio of 22X, ranking 23rd among primary industries [9] - The CPI showed a mild increase of 0.2% in October, with food prices declining by 2.9% [10][11] - Investment recommendations suggest focusing on leading companies with stable demand and strong risk resistance, as well as those innovating in new products and channels [12] - The food and beverage sector maintains a "buy" rating, emphasizing the potential for recovery in the current low valuation environment [12]

Group 1: Macroeconomic Information and Commentary - The Ministry of Industry and Information Technology has issued the "Guidelines for the Construction of High-Standard Digital Parks," aiming to establish around 200 high-standard digital parks by 2027, with effective deployment and application of computing infrastructure [2] - In the third quarter, foreign institutional investors further increased their holdings in Chinese stocks, with the holdings of the top 40 global investment institutions rising to 1.1%, the highest level since the first quarter of 2023 [2] Group 2: Wealth and Investment Trends - In Hong Kong, the population of millionaires is projected to reach 395,000 by 2025, an increase of 5,000 from the previous year, representing about 7% of the local population aged 21 to 79 [3] - The average age for millionaires to earn their "first pot of gold," defined as accumulating 1 million HKD in assets, is 34 years, with initial investments primarily in stocks and funds [3] Group 3: Oil Price Outlook - The outlook for oil prices needs to be observed from short, medium, and long-term perspectives. Short-term factors include geopolitical stability, which could significantly impact oil supply and prices due to ongoing war risks [4] - Medium-term considerations involve global macroeconomic changes and the stability of OPEC+ policies, where a recovering global economy could raise oil demand and prices, while significant internal disagreements within OPEC+ may disrupt production agreements [4] - Long-term factors include technological breakthroughs and the rapid development of renewable energy, which may disrupt traditional fossil fuel demand [4]

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]

Industry Overview - The vaccine industry is experiencing a structural opportunity due to the rising trend of influenza, with a focus on flu vaccine developments [2][4] - Recent approvals for clinical trials include various vaccines from companies like Zhifei Biological, including a pertussis-diphtheria-tetanus vaccine and an mRNA shingles vaccine [2][4] - The National Influenza Center reported an increase in flu activity, with a total of 621 reported influenza-like illness outbreaks across the country [4] Market Performance - The vaccine sector saw a 3% increase, with the overall pharmaceutical and biological sector rising by 3.29% during the week of November 9-15, 2025 [5] - Notable companies in the vaccine sector that performed well include Jindike, Hualan Biological, and Baike Biological, while companies like Wantai Biological and Zhifei Biological lagged [6] Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio (ttm) was 101.87X, reflecting a 2.8X increase week-over-week, while the price-to-book (PB) ratio was 1.99X, up by 0.05X [7][8] Investment Insights - The vaccine industry is under pressure, with a notable structural differentiation among companies. The focus is on innovation and international expansion as key strategies for long-term growth [9] - The industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition causing short-term challenges [9] - Key drivers for the industry's long-term growth include policy support, demand increase due to an aging population, and technological advancements [10] Recommendations - Companies with strong research and development capabilities and differentiated product offerings, such as CanSino and Kanghua Biological, are recommended for investment [10] - Short-term focus should be on companies involved in flu vaccines due to the seasonal increase in demand [10]